BioSpace News Archive

Amylyx Pharmaceuticals, Inc. today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine)) for the treatment of amyotrophic lateral sclerosis (ALS).

Hologic, Inc., a global leader in women’s health, will launch the NovaSure® V5 global endometrial ablation device at the American Association of Gynecologic Laparoscopists 50th Global Congress on.

IVERIC bio, Inc. reported that on November 1, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer.

Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded 510K clearance for Horizon 3.0. Designed specifically for the clinical setting, Horizon 3.0 offers enhanced workflows with navigated TMS and analytics.

PierianDx, the global leader in clinical genomics knowledge, announced that it closed on $30 million of new growth capital including equity financing and a term loan facility, which includes access to additional tranches for up to $17.5 million by 2022 and 2023, subject to certain conditions.

This is the first allowed patent application for CVR Medical at the EPO and an integral part of the CVR IP portfolio with an early priority date of June 24, 2010.

The trial is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate the Company’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy.

Pressure BioSciences, Inc., a leader in the development and sale of innovative, broadly enaabling, pressure-based instruments, consumables, and services to the worldwide life sciences, agriculture, food & beverage, and other key industries, announced the Company’s participation in Benzinga’s November 4th ALL ACCESS Investor Event.

Adaptive Phage Therapeutics, Inc. (APT), today announced that it has entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to support a multi-center Phase 1b/2, randomized, double-blind, placebo-controlled trial assessing the safety and microbiological activity of a single dose of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa.